Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.
The recent discovery of activating mutations in the BRAF gene in many cutaneous melanomas led us to screen the genomic sequence of BRAF exons 11 and 15 in a series of 48 intraocular (uveal) melanomas, together with control samples from three cutaneous melanomas and the SK-Mel-28 cell line, which has a BRAF mutation. The same mutation was detected in two-thirds of our cutaneous melanoma samples, but was not present in any uveal melanomas. This finding further underlines the distinction between uveal and cutaneous melanomas, and suggests that BRAF inhibitors are unlikely to benefit patients with uveal melanoma.
Edmunds
S C
SC
Centre for Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, 2 Newark Street, Whitechapel E1 2AT, UK.
Cree
I A
IA
Dí Nícolantonío
F
F
Hungerford
J L
JL
Hurren
J S
JS
Kelsell
D P
DP
D001483:Base Sequence; D017931:DNA Primers; D004268:DNA-Binding Proteins / Q000235:genetics*; D005091:Exons; D006609:High Mobility Group Proteins; D006801:Humans; D008545:Melanoma / Q000235:genetics* / Q000473:pathology; D009154:Mutation; D015513:Oncogene Proteins / Q000235:genetics*; D016133:Polymerase Chain Reaction; D048493:Proto-Oncogene Proteins B-raf; D012878:Skin Neoplasms / Q000235:genetics* / Q000473:pathology; D014407:Tumor Cells, Cultured; D014604:Uveal Neoplasms / Q000235:genetics* / Q000473:pathology
D017931:DNA Primers; D004268:DNA-Binding Proteins; C000625244:HMG20B protein, human; D006609:High Mobility Group Proteins; D015513:Oncogene Proteins; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf